Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04DNB
|
|||
| Drug Name |
Xentuzumab
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 2 | [1] | |
| Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 1/2 | [2] | ||
| Company |
Boehringer Ingelheim Pharmaceuticals Ridgefield, CT
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Insulin-like growth factor-I (IGF1) | Target Info | . | [2] |
| Insulin-like growth factor-II (IGF2) | Target Info | . | [2] | |
| Pathway Interaction Database | Plasma membrane estrogen receptor signaling | |||
| SHP2 signaling | ||||
| IGF1 pathway | ||||
| Ceramide signaling pathway | ||||
| Integrins in angiogenesis | ||||
| Stabilization and expansion of the E-cadherin adherens junction | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03659136) The XENERA 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.